Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017 – iCrowdNewswire
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Dec 7, 2017 1:35 PM ET

Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017

iCrowdNewswire - Dec 7, 2017

The “Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017” report has been added to Research and Markets’ offering.

Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 14, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

– Introduction
– Gastrointestinal Stromal Tumor (GIST) – Overview
– Gastrointestinal Stromal Tumor (GIST) – Therapeutics Development
– Pipeline Overview
– Pipeline by Companies
– Pipeline by Universities/Institutes
– Products under Development by Companies
– Products under Development by Universities/Institutes
– Gastrointestinal Stromal Tumor (GIST) – Therapeutics Assessment
– Assessment by Target
– Assessment by Mechanism of Action
– Assessment by Route of Administration
– Assessment by Molecule Type
– Gastrointestinal Stromal Tumor (GIST) – Companies Involved in Therapeutics Development

– AB Science SA
– Advanced Accelerator Applications SA
– Ariad Pharmaceuticals Inc
– Arog Pharmaceuticals Inc
– ArQule Inc
– Array BioPharma Inc
– Ascentage Pharma Group Corp Ltd
– Astex Pharmaceuticals Inc
– Blueprint Medicines Corp
– Boston Biomedical Inc
– Calithera Biosciences Inc
– Celldex Therapeutics Inc
– Chipscreen Biosciences Ltd
– Deciphera Pharmaceuticals LLC
– Eli Lilly and Co
– Exelixis Inc
– F. Hoffmann-La Roche Ltd
– Hanmi Pharmaceuticals Co Ltd
– Horizon Pharma Plc
– Immunicum AB
– Jiangsu Hengrui Medicine Co Ltd
– Loxo Oncology Inc
– Merck & Co Inc
– Natco Pharma Ltd
– Nerviano Medical Sciences Srl
– Novartis AG
– Omeros Corp
– Pharma Mar SA
– Plexxikon Inc
– Rhizen Pharmaceuticals SA
– Taiho Pharmaceutical Co Ltd
– Xencor Inc

For more information about this report visit https://www.researchandmarkets.com/research/nccwxn/gastrointestinal?w=3

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
[email protected]
Related Topics: Oncology Drugs (https://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=nccwxn)

Via iCrowdNewswire
View Related News >